INNOFORCE OPENS GMP MANUFACTURING FACILITY & CORPORATE HEADQUARTERS IN HANGZHOU, CHINA TO PROVIDE CDMO SERVICES FOR GLOBAL SUPPLY OF RNA, CELL & GENE THERAPIES

The new site adds to its capacity in China & US to provide end-to-end process development and global manufacturing services for advanced therapies

HANGZHOU, China, December 01, 2022—Innoforce, a global provider of end-to-end contract development and manufacturing services (CDMO), today announced that it commenced GMP manufacturing at its new site in Hangzhou, China. The new facility is built to offer process development & manufacturing services for the global supply of RNA, plasmid DNA, viral vectors, and cell therapeutics through research, clinical and commercial stages. It will also serve as the corporate headquarters for the company.

The company is investing a total of more than $200 million in its 550,000 square-foot advanced therapies manufacturing base with a full suite of technology platforms. The GMP manufacturing space is designed with separate areas for plasmids production with three 30-liter bioreactors, viral vectors production using 200- and 500-liter bioreactors, and cell therapies in up to 8 suites using leading automated production platforms. RNA capabilities include industry-standard in-vitro transcription processing and optimized lipid-nanoparticle (LNP) formulation. In addition, process development & analytics labs, fill-finish lines, and modern warehousing position the site to meet the diverse needs of clients bringing advanced therapies to market.

“Innoforce is committed to enabling innovative RNA, cell, and gene therapeutics, supported by our new world-class manufacturing and development hub and expertise of our professional colleagues,” commented Dr. Yuling Li, Chief Executive Officer of Innoforce. “We’re thrilled to open our new site, which is among the largest RNA, cell & gene therapy manufacturing sites in Asia, and one of few in the world to integrate such a comprehensive platform in one base.”

Dr. Min Zhu, Senior Vice President of CDMO Operations, said, “Building on existing capabilities, including our outstanding workforce, scale, and modern technology platforms, we are well-positioned to help clients overcome common pain points and bring revolutionary advanced therapies to market. We believe our platform can support clients to reduce cycle times, increase efficiency, and ensure supply reliability that meets international regulators’ requirements.”

Innoforce’s RNA, cell & gene therapy site is strategically established within the company’s Bioinnovation Campus at the heart of a rapidly growing biotech innovation corridor in China and is advantageously located near a major international transportation hub and leading universities. The campus is expected to attract other biotherapeutic enterprises, including a biologic drugs manufacturing operation that

Innoforce established with a leading international life sciences supplier. In addition, Innoforce will establish its global headquarters and expects to employ over 300 people on-site by the end of 2023.

About Innoforce

Innoforce is a partnership-focused biopharmaceutical company established to enable and accelerate the innovation of breakthrough Advanced Therapy Medicinal Products and Biologics. Innoforce offers end-to-end contract development and manufacturing service (CDMO), including GMP manufacturing of RNA, plasmid DNA, viral vectors, and cell therapies. In addition, through a joint venture with a leading international supplier of life sciences products and services, the company provides CDMO services for antibody and protein drugs. Innoforce's capabilities for incubating and developing cell, gene, and advanced biological therapies companies to rapidly and efficiently bring cutting-edge treatments that impact patients' lives worldwide. More information is available at https://www.innoforcepharma.com/

Media contact:

Min Zhu, Senior VP, CDMO Operations

cdmo@innoforcepharma.com

Telephone: +86-571-82816679

健新原力全新 GMP 生产基地&公司总部大楼（中国，杭州）投入运营，进一步为全球客户提供 RNA、细胞和基因疗法的 CDMO 一站式服务

-新基地将提高健新原力在中国和美国为先进疗法提供端到端的工艺开发和全球生产服务的能力。

中国杭州，2022 年 12 月 02 日 – 健新原力，一家全球端到端合同研发生产组织（CDMO），今日宣布，公司在中国杭州新建的 GMP 生产基地正式投入运营。该基地作为公司总部，将为全球客户提供从研究、临床到商业化阶段的 RNA、质粒 DNA、病毒载体以及细胞疗法 (先进疗法药物)的 CDMO 一站式服务。

健新原力新园区先进疗法生产基地占地面积达 51,000 平方米，配备一整套技术平台。GMP 生产车间设有单独生产的区域：3 个 30 升生物反应器供应质粒生产、200 升和 500 升生物反应器进行病毒载体生产、以及 8 个配备先进自动生产平台的车间用于细胞疗法。RNA 产能包括符合工业标准的体外转录工艺和优化的脂质纳米粒（LNP）制剂。此外，新园区还配备工艺开发和分析实验室、灌装线路以及现代化仓储，满足客户的多样需求，将先进疗法推向市场。

“健新原力的专业团队将依托这一世界级生产和研发中心，赋能 RNA、细胞与基因疗法的创新，”健新原力首席执行官李玉玲博士表示。“我们很激动看到新基地投入运营，这是亚洲最大的 RNA、细胞和基因治疗的生产基地之一，也是世界上为数不多拥有如此高度整合平台的基地。”

CDMO 运营资深副总裁朱敏博士说道：“我们拥有极为优秀的员工团队、广阔的业务范围以及现代化技术平台。我们已经完全准备好调动这些现有的资源继续发展，帮助客户攻克常见的业务痛点，将具有变革意义的先进疗法推向市场。我们坚信，我们的生产平台能够帮助客户减少周期次数、提高效率、确保供应可靠性，满足国际监管机构的要求。”

健新原力的 RNA、细胞和基因疗法产品的先进疗法生产基地中心坐落于杭州生物科技谷园区内，靠近主要国际交通枢纽和诸多一流大学，享有优越的地理位置。健新原力生物创新园区位于中国快速发展的生物技术创新走廊的中心地带，园区选址具有深远的战略性意

义。该园区将吸引其他生物治疗企业，其中包括健新原力和国际领先的生命科学企业合作建立的生物药生产公司。健新原力将在此建立全球总部，截至 2023 年将拥有约 300 名雇员。

关于健新原力

健新原力是一家专注于合作伙伴关系的生物制药公司，旨在促进和推动突破性先进疗法药物（ATMP）和生物制剂的创新。健新原力提供端到端的合同开发和制造服务（CDMO），包括 RNA、质粒 DNA、病毒载体和细胞疗法产品的 GMP 生产。此外，通过与国际领先的生命科学产品和服务供应商建立的合资公司，健新原力提供抗体和蛋白质药物的 CDMO 服务。健新原力具有培育和开发细胞、基因和先进生物疗法公司的能力，能够快速高效地创造尖端治疗，为全球患者的生活带来改变。更多信息请见 https://www.innoforcepharma.com/。

媒体联系：

CDMO 运营资深副总裁朱敏博士

cdmo@innoforcepharma.com

+86-571-82816679